ANI Pharmaceuticals Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
May 7, 2021 6:52 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.33 better than the analyst estimate of $0.71. Revenue for the quarter came in at $54.5 million versus the consensus estimate of $46.8 million.
First Quarter 2021 Financial Highlights:
Net revenues were $54.5 million compared to $49.8 million in Q1 2020.GAAP net income was $0.1 million, and diluted GAAP earnings per share was $0.01.Adjusted non-GAAP EBITDA was $18.9 million.Adjusted non-GAAP diluted earnings per share was $1.04.Cash and cash equivalents were $25.1 million, net accounts receivable was $91.9 million,... More



